ライフサイエンスコーパス: uricase

1 or, and pegloticase, a pegylated recombinant uricase.

2 a previous phase I trial of subcutaneous PEG-uricase.

3 ro upon binding uric acid, the substrate for uricase.

4 s antagonized by uric acid, the substrate of uricase.

5 fective and less immunogenic than unmodified uricase.

6 ress its own expression as well as that of a uricase, a repression that is alleviated both in vivo an

7 Plasma uricase activity (pUox), the plasma urate concentration

8 of hucR and uricase transcript and increased uricase activity under conditions of excess uric acid fu

9 mans and great apes, which have lost hepatic uricase activity, leading to uniquely high serum uric ac

10 osed mice, the powerful inhibitory effect of uricase administration on allergic sensitization is medi

11 system resulting from enzymatic reaction of uricase and HRP (horseradish peroxidase), which is invol

12 e system demonstrated sufficient activity of uricase and HRP at a ratio of 5U:5U and pH 7.0.

13 by binding a shared promoter region between uricase and HucR genes.

14 s well as urate-lowering therapies including uricase and inhibitors of renal urate transporter protei

15 n shown to repress expression of a predicted uricase, and DNA-binding by HucR is antagonized by uric

16 oxidase inhibitor, febuxostat, and pegylated uricases are in clinical trials.

17 modified recombinant mammalian uricases (PEG-uricase) as a potential therapy for gout and uric acid n

18 nalysis in comparison to clinically approved uricase assay indicated the high accuracy of the present

19 Single infusions of PEG-uricase (at doses ranging from 0.5 mg to 12 mg) were adm

20 models to understand the history of primate uricases by resurrecting ancestral mammalian intermediat

21 iguously that the archetypical cofactor-free uricase catalyzes uric acid degradation via a C5(S)-(hyd

22 e hyperuricemia induced by the inhibition of uricase, caused a robust mobilization of EPCs, whereas a

23 PEG-uricase could provide an effective therapy for uric acid

24 The studies reveal that the uricase/CuO/Pt/glass bio-electrode exhibits good lineari

25 ioelectrocatalytic oxidation of uric acid by uricase/CuO/Pt/glass electrode was studied without any e

26 Uricase-deficient mice develop uric acid nephropathy, wi

27 e uric acid/creatinine ratio in the urine of uricase-deficient mice ranges from 10 to >30; on a weigh

28 Treatment of uricase-deficient mice with PEG-uricase markedly reduced

29 tes and normalized serum uric acid levels in uricase-deficient mice.

30 ors, a nonxanthine oxidase inhibitor and the uricase enzymes have been developed adding to our armame

31 Infusing 4-12 mg of PEG-uricase every 2-4 weeks should maintain the pUAc well be

32 ponsive branch of the MarR family, regulates uricase expression in Deinococcus radiodurans by binding

33 ted recombinant mammalian urate oxidase (PEG-uricase) for the treatment of severe gout.

34 to the silencing or pseudogenization of the uricase gene in ancestral apes.

35 m uric acid due to missense mutations in the uricase gene.

36 occurred even when the enzymatic activity of uricase had been inactivated.

37 12 mM, indicate that the immobilized enzyme (uricase) has enhanced affinity towards its analyte (uric

38 Resurrected proteins reveal that ancestral uricases have steadily decreased in activity since the l

39 etection system consisting of combination of uricase/HRP-CdS quantum dots (QDs) for the determination

40 lts from studies of pegloticase, a pegylated uricase in development, and we summarise data for severa

41 Retention of uricase in most mammals and its loss in humans and some

42 protein concentrations equivalent to that of uricase inhibited NO2-promoted allergic airway disease.

43 ce exposed to NO2 and that administration of uricase inhibited the development of OVA-driven allergic

44 of tolerogenic nanoparticles with pegylated uricase inhibited the formation of ADAs in mice and non-

45 mentally increasing uric acid levels using a uricase inhibitor causes systemic hypertension in animal

46 (induced by continuous 2-wk treatment with a uricase inhibitor oxonic acid), EPC mobilization was blu

47 hyperuricemia in normal rats induced by the uricase inhibitor, oxonic acid (OA), results in hyperten

48 Finally, pharmacokinetics of an ancient uricase injected in rodents suggest that our integrated

49 Uricase is also highly expressed in mouse but not human

50 Uricase is an enzyme involved in purine catabolism and i

51 Curiously, uricase is not functional in some organisms despite its

52 dimensional imaging technique was applied to uricase knockout mice to demonstrate the method for the

53 Treatment of uricase-deficient mice with PEG-uricase markedly reduced urate levels and, when initiate

54 Uricase modified with a comprehensive zwitterionic polyc

55 The enzyme (uricase)-modified screen printed electrode system has be

56 IgG antibodies to PEG-uricase, mostly IgG2 and specific for PEG, developed in

57 The uricase mutation in the Miocene likely provided a surviv

58 PK behavior was unchanged, and neither anti-uricase nor anti-PCB antibodies were detected after thre

59 Here, working with resurrected ancestral uricases obtained from early hominids, we show that thei

60 ylene glycol)-modified recombinant mammalian uricases (PEG-uricase) as a potential therapy for gout a

61 lumen, and removal of this endogenous UA by uricase prevented type 2 immune responses.

62 tionary history by crystallizing a mammalian uricase protein.

63 t (and in opposing orientation) to the human uricase pseudogene.

64 epG2 liver cells to test one hypothesis that uricase pseudogenization allowed ancient frugivorous ape

65 3 A resolution structure of the hypothetical uricase regulator (HucR) from Deinococcus radiodurans R1

66 Hypothetical uricase regulator (HucR), which belongs to the ligand-re

67 rans-encoded MarR homolog HucR (hypothetical uricase regulator) and identified residues responsible f

68 , uricase was itself immunogenic, inducing a uricase-specific adaptive immune response that occurred

69 ntergenic region between hucR and a putative uricase suggests a mechanism of simultaneous co-repressi

70 x was linearly related to the IV dose of PEG-uricase, the area under the curve (AUC) value increased

71 evels than most mammals due to a mutation in uricase, the enzyme involved in uric acid degradation in

72 Uricase, the enzyme that catalyzes conversion of uric ac

73 acid excretion (lesinurad), and recombinant uricase to directly catabolize urate (pegloticase).

74 ific response was not due to the capacity of uricase to inhibit the early steps of OVA uptake or proc

75 The use of modified uricases to rapidly reduce serum urate concentrations in

76 electrocatalytic activity to the immobilized uricase towards the oxidation of analyte (uric acid) and

77 Enhanced levels in vivo of hucR and uricase transcript and increased uricase activity under

78 Uricase (Urc) is an oxidoreductase enzyme of both genera

79 The substrate of uricase, uric acid, is an efficient antagonist of DNA bi

80 d in vitro and hyperuricemic geese, a native uricase via extracorporeal delivery was active in the di

81 PEG-uricase was far more effective and less immunogenic than

82 However, uricase was itself immunogenic, inducing a uricase-speci

83 ene glycol)-conjugated mammalian recombinant uricase, was developed to fulfill this need.

84 events and the IgG antibody response to PEG-uricase were followed up for 35 days.

85 bility, efficacy, and tolerability of IV PEG-uricase were greater than the bioavailability, efficacy,

86 Further, ancient and modern uricases were stably transfected into HepG2 liver cells

87 as determined by blocking the hepatic enzyme uricase with oxonic acid (CSA-OA).